Sensus Healthcare Elects New Director at Annual Meeting

Sensus Healthcare ( (SRTS) ) has issued an announcement.

At the Annual Meeting of Stockholders held on May 27, 2025, Sensus Healthcare elected Anthony Petrelli as a Class I director for a three-year term. Stockholders approved an amendment to the 2017 Incentive Plan, extending its term and increasing the share issuance limit. Additionally, the compensation of the company’s executive officers for 2024 was approved on an advisory basis, and Berkowitz Pollack Brant Advisors + CPAs, LLP was ratified as the independent registered public accountant for the fiscal year ending December 31, 2025.

The most recent analyst rating on (SRTS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Sensus Healthcare stock, see the SRTS Stock Forecast page.

Spark’s Take on SRTS Stock

According to Spark, TipRanks’ AI Analyst, SRTS is a Neutral.

Sensus Healthcare has a solid financial foundation with strong revenue growth and a robust balance sheet. However, cash flow challenges and a high P/E ratio indicate potential overvaluation. Technical indicators suggest a bearish trend, and while the earnings call provided some optimistic future guidance, current financial setbacks such as revenue decline and net loss weigh on the overall score.

To see Spark’s full report on SRTS stock, click here.

More about Sensus Healthcare

Sensus Healthcare operates in the healthcare industry, focusing on providing innovative solutions for non-invasive cancer treatment and other skin conditions. The company is known for its SRT-100 product line, which offers superficial radiation therapy for treating non-melanoma skin cancers and keloids.

Average Trading Volume: 112,596

Technical Sentiment Signal: Sell

Current Market Cap: $78.28M

See more insights into SRTS stock on TipRanks’ Stock Analysis page.